Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $18.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 297.35% from the company’s previous close.
Separately, StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a research note on Tuesday. They set a “hold” rating for the company.
View Our Latest Research Report on Vanda Pharmaceuticals
Vanda Pharmaceuticals Trading Up 2.0 %
Insider Buying and Selling
In related news, Director Stephen Ray Mitchell sold 5,000 shares of the business’s stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $5.17, for a total transaction of $25,850.00. Following the completion of the transaction, the director now directly owns 44,857 shares in the company, valued at $231,910.69. The trade was a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.90% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Vanda Pharmaceuticals
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Nantahala Capital Management LLC boosted its holdings in shares of Vanda Pharmaceuticals by 57.3% in the 2nd quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company’s stock worth $9,003,000 after purchasing an additional 580,265 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Vanda Pharmaceuticals by 17.0% during the second quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company’s stock worth $11,379,000 after acquiring an additional 292,172 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter worth approximately $864,000. Geode Capital Management LLC grew its holdings in shares of Vanda Pharmaceuticals by 7.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,425,827 shares of the biopharmaceutical company’s stock valued at $6,689,000 after purchasing an additional 94,870 shares during the last quarter. Finally, Barclays PLC increased its stake in shares of Vanda Pharmaceuticals by 128.2% in the third quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company’s stock worth $722,000 after buying an additional 86,677 shares during the period. Hedge funds and other institutional investors own 88.14% of the company’s stock.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Further Reading
- Five stocks we like better than Vanda Pharmaceuticals
- Russell 2000 Index, How Investors Use it For Profitable Trading
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- What is the FTSE 100 index?
- 3 Steel Stocks Soaring After Tariff Announcements
- Want to Profit on the Downtrend? Downtrends, Explained.
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.